The present disclosure provides methods and compositions that find use in facilitating a diagnosis of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in a subject. The methods and compositions involve measurement of at least one of proteins: IL-16, IL-7, VEGF, CXCL9, CX3CL1, CCL24, CCL19, and CCL11 in a body fluid sample of a subject suspected of having CFS/ME. Levels of one or more of the aforementioned proteins can be used to facilitate a diagnosis of a CFS/ME and/or confirm a diagnosis of CFS/ME. The methods and compositions of the present disclosure also find use in screening subjects for clinical trials and facilitating treatment decisions for a subject.

A method for diagnosing of or for determining the risk of developing Alzheimer's disease, as well as for determining the presence of severe AD in a subject involves at least four specific biomarkers being measured. A kit or an array comprising a detecting means, in particular antibodies, for at least four specific biomarkers can be used for the diagnosis. Further, a computer program product and a computer implemented method for diagnosing of or determining the risk of developing Alzheimer's disease may be employed.

A method for monitoring fetal and/or preterm infant development and a method to promote normal growth & development of preterm infants, especially in regards to each preterm infant's collective set of immature organs. Monitoring development is accomplished by using VEGF 121 as a biomarker in bodily fluid levels, to determine whether appropriate angiogenic activity is occurring to allow preterm infant or fetal development to proceed normally. The promotion of preterm infant normal development is accomplished by administering to a preterm infant human chorionic gonadotropin (hCG) and/or Luteinizing hormone (LH) and/or Luteinizing hormone releasing hormone (LHRH) in physiological amounts at appropriate intervals to raise and maintain the activation level of the patient's combined hCG/LH receptor activity, or VEGF 121 level, to a level that is normally present in fetuses of the equivalent developmental (gestational) age. By promoting normal development, we prevent onset or progression of disorders associated with premature organs rather than treat disorders associated with the premature organs after they occur.

VEGFA-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the VEGFA-binding molecules.

VEGFA-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the VEGFA-binding molecules.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

Methods for detecting angiopoietin-2 (Angpt-2) and/or thrombospondin-2 (Tsp-2) in a sample involve obtaining or having obtained a blood or plasma sample from a subject; and detecting or Angpt-2 and Tsp-2 in the sample. Detecting can involve performing an assay to determine whether the sample includes Angpt-2 and/or Tsp-2 or elevated levels of Angpt-2 and/or Tsp-2. Elevated levels are indicative of acute heart failure.

The invention relates to the C-terminal fragment of angiopoietin-related protein 4 [cAngptl4] as a diagnostic marker for viral and bacterial pneumonia; anti-angiopoietin-related protein 4 therapeutic antibodies, and the use of anti-angiopoietin-related protein 4 antibodies in the treatment of viral and bacterial pneumonia.

A method of guiding medical treatment of patients receiving an intravitreal injection are described. The method includes obtaining a vitreous sample from a subject receiving an intravitreal injection first treatment, determining the biomarker signature of the sample, reporting the biomarker signature of the sample, and changing the method of treatment to a second treatment if the biomarker signature indicates that use of the second treatment will have a preferable outcome.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.